These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1402063)

  • 1. [In vitro antimicrobial activity of DR-3355, a new quinolone antibacterial agent, against clinical isolates of enteritis-causing bacteria].
    Horiuchi S; Inagaki Y; Yamamoto N; Ogawa M; Nakaya R
    Kansenshogaku Zasshi; 1992 Jan; 66(1):51-8. PubMed ID: 1402063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antibacterial activity of pazufloxacin (PZFX) against clinical isolates from infectious enteritis].
    Fukuyama M; Oonaka K; Hara M; Imagawa Y
    Kansenshogaku Zasshi; 1996 Jan; 70(1):51-9. PubMed ID: 8822053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antibacterial activity of fleroxacin (FLRX) against clinical isolates from bacterial enteritis].
    Imagawa Y; Fukuyama M; Kawakami K; Suda O
    Kansenshogaku Zasshi; 1994 Nov; 68(11):1409-16. PubMed ID: 7829909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
    Fukuyama M; Kawakami K; Suda O; Imagawa Y
    Kansenshogaku Zasshi; 1995 Sep; 69(9):987-90. PubMed ID: 7594800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antimicrobial activity of rokitamycin, a macrolide antibacterial agent, against clinically isolated strains of Campylobacter and other enteritis-causing bacteria].
    Horiuchi S; Inagaki Y; Chida T; Nakaya R
    Kansenshogaku Zasshi; 1991 Oct; 65(10):1325-30. PubMed ID: 1791330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Sajima Y; Sagara H; Kato H; Hosoda S; Banba T; Sasaki M; Yoshikawa K; Nakagawa M; Ohkubo H; Kim Y; Akao M; Fukuyama M
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea.
    Inagaki Y; Horiuchi S; Une T; Nakaya R
    J Antimicrob Chemother; 1989 Oct; 24(4):547-9. PubMed ID: 2613604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibacterial activity of ciprofloxacin against fresh clinical isolates from superficial suppurative foci].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1991 Feb; 44(2):117-29. PubMed ID: 2041153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibilities of Escherichia coli, Salmonella and Staphylococcus aureus isolated from animals to ofloxacin and commonly used antimicrobial agents].
    Takahashi I; Yoshida T; Higashide Y; Sakano T
    Jpn J Antibiot; 1990 Jan; 43(1):89-99. PubMed ID: 2190017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trial of T-3262 on acute enteritis. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
    Aoki T; Matsubara Y; Sagara H; Tomizawa I; Takizawa Y; Nitta Y; Seo T; Kamimura M; Masuda G; Negishi M
    Kansenshogaku Zasshi; 1989 Jun; 63(6):593-605. PubMed ID: 2693541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The drug susceptibility pattern of the presumed etiologic agents of infectious enteritis including verotoxin-producing Escherichia coli O-157].
    Deguchi K; Suzuki Y; Ishihara R; Ishii Y; Nakazawa A
    Jpn J Antibiot; 1997 Oct; 50(10):829-43. PubMed ID: 9412873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
    Fukuyama M; Furuhata K; Oonaka K; Hara T; Sunakawa K
    Jpn J Antibiot; 2000 Jul; 53(7):522-31. PubMed ID: 11019386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical studies on the treatment of Campylobacter enteritis--emergence of quinolone-resistant Campylobacter jejuni after treatment with new quinolones].
    Obana M; Matsuoka Y; Irimajiri S; Tonooka H
    Kansenshogaku Zasshi; 1992 Jul; 66(7):923-9. PubMed ID: 1431368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative in-vitro activity of ofloxacin.
    Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.